CN111372930A - 一种SGLTs抑制剂及其应用 - Google Patents

一种SGLTs抑制剂及其应用 Download PDF

Info

Publication number
CN111372930A
CN111372930A CN201980005940.0A CN201980005940A CN111372930A CN 111372930 A CN111372930 A CN 111372930A CN 201980005940 A CN201980005940 A CN 201980005940A CN 111372930 A CN111372930 A CN 111372930A
Authority
CN
China
Prior art keywords
compound
group
pharmaceutically acceptable
isomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005940.0A
Other languages
English (en)
Other versions
CN111372930B (zh
Inventor
吴成德
毛庆华
李翼
于涛
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Shandong Danhong Pharmaceutical Co Ltd
Original Assignee
Shandong Danhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Danhong Pharmaceutical Co Ltd filed Critical Shandong Danhong Pharmaceutical Co Ltd
Publication of CN111372930A publication Critical patent/CN111372930A/zh
Application granted granted Critical
Publication of CN111372930B publication Critical patent/CN111372930B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

作为SGLT1/SGLT2双重抑制剂的化合物，以及在制备作为SGLT1/SGLT2双重抑制剂的药物中的应用。所述化合物是式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980005940.0A 2018-01-05 2019-01-04 一种SGLTs抑制剂及其应用 Active CN111372930B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810012284 2018-01-05
CN2018100122844 2018-01-05
PCT/CN2019/070336 WO2019134667A1 (zh) 2018-01-05 2019-01-04 一种SGLTs抑制剂及其应用

Publications (2)

Publication Number Publication Date
CN111372930A true CN111372930A (zh) 2020-07-03
CN111372930B CN111372930B (zh) 2021-08-10

Family

ID=67144362

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980005940.0A Active CN111372930B (zh) 2018-01-05 2019-01-04 一种SGLTs抑制剂及其应用

Country Status (10)

Country Link
US (1) US10822365B1 (zh)
EP (1) EP3712147B8 (zh)
JP (1) JP6917527B2 (zh)
KR (1) KR102283677B1 (zh)
CN (1) CN111372930B (zh)
AU (1) AU2019205072B2 (zh)
ES (1) ES2941108T3 (zh)
FI (1) FI3712147T3 (zh)
PT (1) PT3712147T (zh)
WO (1) WO2019134667A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020200153A1 (zh) * 2019-03-29 2020-10-08 南京明德新药研发有限公司 作为sglt1抑制剂的葡糖苷类衍生物及其应用
JP7273997B2 (ja) * 2019-07-05 2023-05-15 山東丹紅制薬有限公司 Ｓｇｌｔ阻害剤の結晶形及びその使用
CA3145678C (en) * 2019-07-26 2022-08-23 Medshine Discovery Inc. Sglt2/dpp4 inhibitor and application thereof
CN116322675A (zh) * 2020-09-27 2023-06-23 南京明德新药研发有限公司 葡糖苷类化合物的晶型及其应用
WO2022160737A1 (zh) * 2021-01-26 2022-08-04 东宝紫星(杭州)生物医药有限公司 四氢吡喃环类化合物的晶型及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042688A2 (en) * 2006-09-29 2008-04-10 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
CN101503399A (zh) * 2008-02-04 2009-08-12 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
CN102146066A (zh) * 2010-02-05 2011-08-10 天津药物研究院 一类含饱和六元环的c-葡萄糖苷衍生物、其制备方法和用途
CN102453026A (zh) * 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
CN103458875A (zh) * 2011-01-05 2013-12-18 莱西肯医药有限公司 包含钠-葡萄糖协同转运蛋白1和2的抑制剂的组合物及使用方法
CN104109154A (zh) * 2013-04-17 2014-10-22 上海阳帆医药科技有限公司 C-芳基葡萄糖苷衍生物及其制备方法和应用
WO2015032272A1 (zh) * 2013-09-09 2015-03-12 江苏豪森药业股份有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772449B (zh) * 2012-10-26 2017-12-26 上海阳帆医药科技有限公司 C‑芳基葡萄糖苷衍生物及其制备方法与用途
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042688A2 (en) * 2006-09-29 2008-04-10 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
CN101503399A (zh) * 2008-02-04 2009-08-12 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
CN102146066A (zh) * 2010-02-05 2011-08-10 天津药物研究院 一类含饱和六元环的c-葡萄糖苷衍生物、其制备方法和用途
CN102453026A (zh) * 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
CN103458875A (zh) * 2011-01-05 2013-12-18 莱西肯医药有限公司 包含钠-葡萄糖协同转运蛋白1和2的抑制剂的组合物及使用方法
CN104109154A (zh) * 2013-04-17 2014-10-22 上海阳帆医药科技有限公司 C-芳基葡萄糖苷衍生物及其制备方法和应用
WO2015032272A1 (zh) * 2013-09-09 2015-03-12 江苏豪森药业股份有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
FI3712147T3 (fi) 2023-04-04
US10822365B1 (en) 2020-11-03
WO2019134667A1 (zh) 2019-07-11
KR102283677B1 (ko) 2021-07-29
EP3712147B1 (en) 2023-01-25
EP3712147A4 (en) 2021-01-13
ES2941108T3 (es) 2023-05-16
EP3712147A1 (en) 2020-09-23
PT3712147T (pt) 2023-03-21
AU2019205072A1 (en) 2020-07-23
JP2021506948A (ja) 2021-02-22
JP6917527B2 (ja) 2021-08-11
KR20200106156A (ko) 2020-09-11
EP3712147B8 (en) 2023-04-26
US20200331950A1 (en) 2020-10-22
AU2019205072B2 (en) 2021-03-04
CN111372930B (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
CN111372930B (zh) 一种SGLTs抑制剂及其应用
KR102588241B1 (ko) 5원 헤테로방향족 이미다졸 화합물 및 이의 용도
CN110446712B (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
WO2021249492A1 (zh) 甲基取代的苯并二噁唑类化合物及其应用
CN111465598B (zh) 作为SGLTs抑制剂的葡糖苷类衍生物及其应用
EP3536698B1 (en) Lanosterol prodrug compound and use thereof
CN111542520B (zh) 作为a2a受体抑制剂的并环类衍生物
CN112159401B (zh) 偏向性激动剂及其医药用途
CN114585358B (zh) 一种SGLTs/DPP4抑制剂及其应用
JP2021510164A (ja) Ｃｘｃｒ２アンタゴニスト
US11358950B2 (en) SMAC mimetics used as IAP inhibitors and use thereof
CN113825750B (zh) 作为sglt1抑制剂的葡糖苷类衍生物及其应用
CN111556869A (zh) 作为csf-1r抑制剂的杂环化合物及其应用
WO2019120212A1 (zh) Ido抑制剂
WO2021104470A1 (zh) 抗hbv的1,7-萘啶类化合物
BR112022023879B1 (pt) Composto de imidazol heteroaromático com cinco membros e seu uso

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40021796

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant